Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide.
about
Emerging drugs for Guillain-Barré syndromeCritical pathogenic events underlying progression of neurodegeneration in glaucomaActivity-dependent regulation of mitochondrial motility by calcium and Na/K-ATPase at nodes of Ranvier of myelinated nerves.A Brain-Derived Neurotrophic Factor-Based p75NTR Peptide Mimetic Ameliorates Experimental Autoimmune Neuritis Induced Axonal Pathology and Demyelination.Mitochondrial immobilization mediated by syntaphilin facilitates survival of demyelinated axons.Mesenchymal stem cells lack efficacy in the treatment of experimental autoimmune neuritis despite in vitro inhibition of T-cell proliferation.Pathogenesis and treatment of immune-mediated neuropathies.Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability?Treatment of Guillain-Barré syndrome and CIDP.Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial.Sodium channels and multiple sclerosis: roles in symptom production, damage and therapy.Loss of Na+ channel beta2 subunits is neuroprotective in a mouse model of multiple sclerosis.Sodium and potassium currents influence Wallerian degeneration of injured Drosophila axons.Guillain-Barré syndrome: update on immunobiology and treatment.Treatment in inflammatory neuropathies.The strategies used for treatment of experimental autoimmune neuritis (EAN): a beneficial effect of glatiramer acetate administered intraperitoneally.Sustained-release fampridine and the role of ion channel dysfunction in multiple sclerosis.Disease-modifying treatments for progressive multiple sclerosis.Concepts for regulation of axon integrity by enwrapping glia.Sodium channels in astroglia and microglia.Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.Diuretic-sensitive electroneutral Na+ movement and temperature effects on central axonsSafinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.Small nerve fibres, small hands and small feet: a new syndrome of pain, dysautonomia and acromesomelia in a kindred with a novel NaV1.7 mutation.Persistence of intact retinal ganglion cell terminals after axonal transport loss in the DBA/2J mouse model of glaucoma.Trapped in the epineurium: early entry into the endoneurium is restricted to neuritogenic T cells in experimental autoimmune neuritis
P2860
Q22241376-D148F211-AFF5-426D-8330-6275114C19B9Q26859194-317CA63F-0275-450C-B01E-8325754EA077Q30532624-E0961CCC-37D0-43C3-8422-5C8C76B858F6Q33868439-4914DFB9-FBB6-4657-BB1B-91EBB352E9C1Q33919516-AE737800-0B08-4E5A-99CC-0C24306BDB39Q34168051-6F8C628B-6440-45E2-A022-58469D59133CQ34409385-0DA37CCA-3FE0-4648-8429-21D7981E5B73Q34570124-97DB1A30-042A-4BC4-A121-6FD4C0F1667BQ36164126-FD39204E-06E8-4E38-8EAD-3832D1466D7AQ36437641-070A2AA6-0C06-4D79-9FA2-581A41B1AFD7Q36771880-E14A2A73-2767-4C2C-8127-4DAA0B019EEBQ37161778-80792977-08B3-47FA-8606-3E9E1EB3F072Q37345123-637BC011-96B7-452B-B3AA-665C888D89FAQ37600859-9CF12D3D-36B0-4579-8771-828205B5B191Q37733512-EB04C282-D9BA-43F3-A3EA-E129769130F9Q37828450-B554170D-A3D0-4B1D-BD15-536CE964FA7CQ38053131-0A1310A1-24FF-4057-8510-68A64E99BC48Q38142030-1175D05B-E1A2-4D41-849E-049BB4ADFADCQ38175969-E549FCD8-093A-49A6-889F-AA26A8F3DB34Q38751614-760EFB39-CCAB-4EBB-8615-A0CC0D0DC8B8Q38837294-7510B9B0-6B03-48DE-AB20-4C0F014587B2Q38954319-1A8C4ACF-6F66-4004-8C6F-2CCAE527EA81Q46490485-1E9231A0-00A2-4F10-BF0C-A51627FA3FB8Q48686306-C86FD875-9698-4114-ABE6-E8BF8A578BC1Q52140489-ED26AFA9-DF6D-4E3E-ABCB-340FCB6047DFQ58805914-99D3484B-D718-4DB6-BD36-0BBCCD211130
P2860
Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Axonal protection in experimen ...... nel blocking agent flecainide.
@en
Axonal protection in experimen ...... nel blocking agent flecainide.
@nl
type
label
Axonal protection in experimen ...... nel blocking agent flecainide.
@en
Axonal protection in experimen ...... nel blocking agent flecainide.
@nl
prefLabel
Axonal protection in experimen ...... nel blocking agent flecainide.
@en
Axonal protection in experimen ...... nel blocking agent flecainide.
@nl
P2093
P356
P1433
P1476
Axonal protection in experimen ...... nnel blocking agent flecainide
@en
P2093
Meirion Davies
Norman A Gregson
Richard M Evans
P356
10.1093/BRAIN/AWH328
P407
P577
2004-10-27T00:00:00Z